Continuous Renal Replacement Therapy (CRRT) Market to Grow at a CAGR of 8.0% over 2025 to 2032; Growing Prevalence of AKI to Drive Market Growth

The global Continuous Renal Replacement Therapy (CRRT) market size was valued at USD 1.16 billion in 2024. The market is projected to grow from USD 1.25 billion in 2025 to USD 2.14 billion by 2032, exhibiting a CAGR of 8.0% during the forecast period. Fortune Business Insights™ presents this information in its report titled “Continuous Renal Replacement Therapy (CRRT) Market Size, Share & Industry Analysis, By Product Type (Systems and Consumables (Dialysates, Replacement Solutions, Filters, Catheters, and Others)), By Modality (Slow Continuous Ultra Filtration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF)), and Regional Forecast, 2025-2032”.

Continuous Renal Replacement Therapy (CRRT) is a 24-hour dialysis method for critically ill patients with hemodynamic instability and acute kidney injury (AKI). It removes waste and fluids gradually, reducing the risk of sudden hemodynamic changes and mimicking natural kidney function, especially in multi-organ failure cases. The market is expected to ramp up owing to several factors such as a rise in ICU admissions, rising prevalence of sepsis-related AKI, and introduction of new products.

The global CRRT market witnessed positive growth during the COVID-19 pandemic, with Baxter's Acute Therapies segment achieving a 38.3% revenue rise in 2020, largely due to the surge in CRRT system demand for AKI treatment in COVID-19 patients. Increased AKI cases and growing adoption of CRRT systems are poised to drive further market growth.

Baxter International Inc.’s Strategic Roadmap to Boost Its Market Position

In January 2023, Baxter International Inc. announced a strategic roadmap to by combining its Renal Care and Acute Therapies global business units to enhance its operational effectiveness. The plan includes amalgamating into an independent company.

Technological Advancements in CRRT Systems and Increasing Preference of CVVHDF Modality to Accentuate Market Growth

Continuous monitoring in CRRT systems, including improvement in biocompatible membranes, fluid management, and automation, is enhancing treatment efficiency. Integration of AI and remote monitoring allows for real-time data analysis, enabling timely, precise interventions for critically ill patients. Moreover, the rising prevalence of AKI, largely driven by chronic conditions such as hypertension, diabetes, and cardiovascular diseases, is significantly expanding the need for CRRT. As more patients require renal support, especially in ICUs, the demand for CRRT devices and services continues to grow.

However, financial constraints lead many healthcare facilities to opt for affordable dialysis methods, hindering Continuous Renal Replacement Therapy (CRRT) market growth.

Industry Participants Emphasis on Partnerships to Improve Patient Care

 The Continuous Renal Replacement Therapy (CRRT) market is consolidated, with some of the leading players such as Fresenius Medical Care AG & Co. KGaA and B Braun SE dominating in 2024. Fresenius’s PRISMAFLEX system and global dialysis network, while Baxter’s AK 98 CRRT machine strengthens its position with advanced fluid management technology to improve patient care. Companies such as Nipro, Asahi Kasei Medical Co., Ltd., and Medtronic focus on innovations, partnerships, and strategic acquisitions, such as B. Braun’s 2022 acquisition of Intermedt Medizin & Technik GmbH, enhancing its dialysis portfolio.

List of Key Players Mentioned in the Report:

• Baxter (U.S.)


• B Braun SE (Germany)


• Fresenius Medical Care AG & Co. KGaA (Germany)


• Asahi Kasei Medical Co., Ltd. (Asahi Kasei Corporation) (Japan)


• NIPRO (Japan)


• TORAY MEDICAL CO, LTD. (TORAY INDUSTRIES, INC.) (Japan)


• Nikkiso Co., Ltd. (Japan)


• Medtronic (Ireland)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/continuous-renal-replacement-therapy-crrt-market-102547

Key Industry Development:

• July 2024: NIPRO set its first manufacturing facility in North Carolina with an aim to expand its business in the region.

Further Report Findings

• North America captured the key Continuous Renal Replacement Therapy (CRRT) market share and generated USD 0.46 billion in 2024, fueled by high AKI prevalence and CRRT adoption in the U.S. and Canada. The U.S. led the region, supported by rising AKI cases and new products such as Medtronic’s Carpediem cardio-renal pediatric dialysis emergency machine launched in December 2020.


• The Latin America market is expected to expand considerably due to growing CRRT usage, rising AKI incidence, and partnerships with global players to introduce advanced products. Notably in June 2020, CytoSorbents Corporation introduced the CytoSorb blood purification technology in the region to treat COVID-19 and AKI patients, improving survival rates with CRRT integrations.


• Based on product type, consumables segment held the dominant position in the market in 2024. The COVID-19 pandemic significantly increased the occurrence of AKI, boosting the demand for consumable products. Additionally, the global rise in AKI cases further fuels growth in this segment.


• As per modality, Continuous Venovenous Hemodiafiltration (CVVHDF) segment captured the key market share due to its optimal solute clearance through diffusion and convection.  A 2022 survey conducted by conducted by Critical Care Nephrology Section of the European Society of Pediatric and Neonatal Intensive Care revealed that 51% of healthcare professionals preferred this modality, further underscoring its rising adoption.

Table of Segmentation